Trial · NCT06896994
Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
NCT06896994, Not applicable, Recruiting, Beijing Tiantan Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia. Trials, record NCT06896994. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06896994
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
- NCT number
- NCT06896994
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Beijing Tiantan Hospital
- Conditions
- Postherpetic Neuralgia
- Interventions
- esketamine group, control group
- First posted
- 2025-03-26
- Last updated
- 2025-04-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the mean of daily pain scores | during 1 week | the mean of daily pain scores collected during week 1 of treatment measured using the Numerical Pain Rating Scale (NRS,, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain). |
| Secondary | Averaged weekly NRS score | 1 week, 2 weeks, 3 weeks, and 1 month after treatment | Averaged weekly NRS score of each participant.Generally, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain |
| Secondary | percentages of patients having >50% reductions in 24-hour average pain severity during the first week | during the first week | percentages of patients having \>50% reductions |
| Secondary | the 12-item Short-Form Health Survey (SF-12) score | 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment | Quality of life (QoL) assessed by the SF-12 score (range 0-100, with higher scores indicating better health status). |
| Secondary | the Pittsburgh Sleep Quality Index (PSQI) score | 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment | Sleep quality measured by PSQI score (range 0-21, with higher scores indicating poorer sleep quality). |
| Secondary | the Patient Global Impression of Change scale (PGIC) | 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment | The proportion of patients with a response of "no change", "minimally improved", "much improved" or "very much improved" on PGIC. |
| Secondary | The Hospital Anxiety and Depression Scale (HADS) | 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment | It consists of two sub-scales. Each sub-scale consists of 7 items and each item scored from 0 to 3. A higher score indicates more severe anxiety or depression. A score of 11 or above can indicate clinically significant anxiety or depression. |
| Secondary | Averaged weekly analgesic consumption | 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment | Averaged weekly consumption per analgesic of each participant |
| Secondary | Safety assessments | 0 day, 1 day, 3 days, 7 days, 2 weeks,3 weeks, and 1 month after treatment | drug-related complications,such as dizziness, somnolence, gait disturbance, nausea, fatigue, diarrhea, dry mouth, mental symptom, etc |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06896994
GET https://conductscience.org/api/trials/v1/NCT06896994/registered